These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27272046)

  • 1. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.
    Mas S; Gassó P; Lafuente A; Bioque M; Lobo A; Gonzàlez-Pinto A; Olmeda MS; Corripio I; Llerena A; Cabrera B; Saiz-Ruiz J; Bernardo M;
    Pharmacogenomics J; 2016 Oct; 16(5):439-45. PubMed ID: 27272046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
    Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
    Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
    Mas S; Gassó P; Ritter MA; Malagelada C; Bernardo M; Lafuente A
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):51-9. PubMed ID: 25499605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
    Gunes A; Scordo MG; Jaanson P; Dahl ML
    Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.
    Güzey C; Scordo MG; Spina E; Landsem VM; Spigset O
    Eur J Clin Pharmacol; 2007 Mar; 63(3):233-41. PubMed ID: 17225991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2015 Oct; 15(5):452-60. PubMed ID: 25623440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.
    Gassó P; Mas S; Bioque M; Cabrera B; Lobo A; González-Pinto A; Díaz-Caneja CM; Corripio I; Vieta E; Castro-Fornieles J; Sarró S; Mané A; Sanjuan J; Llerena A; Lafuente A; Saiz-Ruiz J; Bernardo M;
    J Psychopharmacol; 2018 Jun; 32(6):702-710. PubMed ID: 29767567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gasso P; Deulofeu R; Mane A; Catalan R; Carne X
    Psychiatry Res; 2008 Nov; 161(2):131-41. PubMed ID: 18922583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
    Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.
    Boloc D; Rodríguez N; Torres T; García-Cerro S; Parellada M; Saiz-Ruiz J; Cuesta MJ; Bernardo M; Gassó P; Lafuente A; Mas S; Arnaiz JA
    Psychopharmacology (Berl); 2020 Jul; 237(7):2151-2159. PubMed ID: 32382784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
    Gassó P; Mas S; Oliveira C; Bioque M; Parellada E; Bernardo M; Trias G; Comeche J; Lafuente A
    Eur Neuropsychopharmacol; 2011 Apr; 21(4):294-9. PubMed ID: 20619616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
    Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
    Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
    Corripio I; Ferreira A; Portella MJ; Pérez V; Escartí MJ; Del Valle Camacho M; Sauras RB; Alonso A; Grasa EM; Carrió I; Catafau AM; Alvarez E
    Psychiatry Res; 2012 Jan; 201(1):73-7. PubMed ID: 22281201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
    Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
    Kirnichnaya KA; Sosin DN; Ivanov MV; Mikhaylov VA; Ivashchenko DV; Ershov EE; Taraskina AE; Nasyrova RF; Krupitsky EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4):113-125. PubMed ID: 26322366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.